SA92130214B1 - انتاج اريثروبوينين Erythropoietin - Google Patents
انتاج اريثروبوينين Erythropoietin Download PDFInfo
- Publication number
- SA92130214B1 SA92130214B1 SA92130214A SA92130214A SA92130214B1 SA 92130214 B1 SA92130214 B1 SA 92130214B1 SA 92130214 A SA92130214 A SA 92130214A SA 92130214 A SA92130214 A SA 92130214A SA 92130214 B1 SA92130214 B1 SA 92130214B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- dna
- polypeptide
- epo
- erythropoietin
- sequence
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 238
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 106
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 105
- 229940105423 erythropoietin Drugs 0.000 title claims abstract description 105
- 108020004414 DNA Proteins 0.000 claims abstract description 152
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 118
- 238000000034 method Methods 0.000 claims abstract description 114
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 111
- 229920001184 polypeptide Polymers 0.000 claims abstract description 98
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 92
- 238000004519 manufacturing process Methods 0.000 claims abstract description 72
- 239000013612 plasmid Substances 0.000 claims abstract description 66
- 241000282693 Cercopithecidae Species 0.000 claims abstract description 50
- 239000002299 complementary DNA Substances 0.000 claims abstract description 34
- 230000014509 gene expression Effects 0.000 claims abstract description 28
- 230000004071 biological effect Effects 0.000 claims abstract description 21
- 230000003612 virological effect Effects 0.000 claims abstract description 15
- 239000013603 viral vector Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 164
- 102000053602 DNA Human genes 0.000 claims description 138
- 108090000623 proteins and genes Proteins 0.000 claims description 96
- 241000282414 Homo sapiens Species 0.000 claims description 65
- 239000013598 vector Substances 0.000 claims description 54
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 50
- 102000044890 human EPO Human genes 0.000 claims description 50
- 230000015572 biosynthetic process Effects 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 22
- 238000003786 synthesis reaction Methods 0.000 claims description 22
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 21
- 210000003743 erythrocyte Anatomy 0.000 claims description 18
- 230000002068 genetic effect Effects 0.000 claims description 17
- 210000002700 urine Anatomy 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 11
- 102000001554 Hemoglobins Human genes 0.000 claims description 9
- 108010054147 Hemoglobins Proteins 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 210000001995 reticulocyte Anatomy 0.000 claims description 5
- 230000002485 urinary effect Effects 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 4
- 108700026244 Open Reading Frames Proteins 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000002798 bone marrow cell Anatomy 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 3
- 230000008827 biological function Effects 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 230000001279 glycosylating effect Effects 0.000 claims description 2
- 102100036514 Amyloid-beta A4 precursor protein-binding family A member 1 Human genes 0.000 claims 1
- 101710093637 Amyloid-beta A4 precursor protein-binding family A member 1 Proteins 0.000 claims 1
- 108010077544 Chromatin Proteins 0.000 claims 1
- 108020004638 Circular DNA Proteins 0.000 claims 1
- 102000007513 Hemoglobin A Human genes 0.000 claims 1
- 108010085682 Hemoglobin A Proteins 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000003483 chromatin Anatomy 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 15
- 229940088597 hormone Drugs 0.000 abstract description 15
- 239000005556 hormone Substances 0.000 abstract description 15
- 239000001963 growth medium Substances 0.000 abstract description 13
- 230000001900 immune effect Effects 0.000 abstract description 11
- 102000040430 polynucleotide Human genes 0.000 abstract description 11
- 108091033319 polynucleotide Proteins 0.000 abstract description 11
- 239000002157 polynucleotide Substances 0.000 abstract description 11
- 238000000338 in vitro Methods 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 10
- 230000001976 improved effect Effects 0.000 abstract description 9
- 241000124008 Mammalia Species 0.000 abstract description 7
- 108091029865 Exogenous DNA Proteins 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 230000001413 cellular effect Effects 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000006166 lysate Substances 0.000 abstract 1
- 102100031939 Erythropoietin Human genes 0.000 description 134
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 129
- 239000000047 product Substances 0.000 description 77
- 239000000523 sample Substances 0.000 description 65
- 150000001413 amino acids Chemical class 0.000 description 55
- 238000009396 hybridization Methods 0.000 description 40
- 239000012634 fragment Substances 0.000 description 32
- 239000002773 nucleotide Substances 0.000 description 32
- 125000003729 nucleotide group Chemical group 0.000 description 32
- 108020004999 messenger RNA Proteins 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 21
- 108091034117 Oligonucleotide Proteins 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 238000003127 radioimmunoassay Methods 0.000 description 17
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 229960000485 methotrexate Drugs 0.000 description 16
- 230000000813 microbial effect Effects 0.000 description 16
- 238000000926 separation method Methods 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 108010022394 Threonine synthase Proteins 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 101150002621 EPO gene Proteins 0.000 description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 102000004419 dihydrofolate reductase Human genes 0.000 description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 208000007502 anemia Diseases 0.000 description 9
- 239000012531 culture fluid Substances 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 102100031780 Endonuclease Human genes 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108700005078 Synthetic Genes Proteins 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000002751 oligonucleotide probe Substances 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- 101150074155 DHFR gene Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 5
- 241000473945 Theria <moth genus> Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005352 clarification Methods 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 244000191761 Sida cordifolia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 3
- 229960004719 nandrolone Drugs 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000287227 Fringillidae Species 0.000 description 2
- 101000801195 Homo sapiens TLE family member 5 Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000009402 cross-breeding Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004216 mammary stem cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LDHYTBAFXANWKM-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one Chemical compound O=C1NC(N)=NC2=C1NC=N2.O=C1NC(N)=NC2=C1N=CN2 LDHYTBAFXANWKM-UHFFFAOYSA-N 0.000 description 1
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 1
- DIDGPCDGNMIUNX-UUOKFMHZSA-N 2-amino-9-[(2r,3r,4s,5r)-5-(dihydroxyphosphinothioyloxymethyl)-3,4-dihydroxyoxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=S)[C@@H](O)[C@H]1O DIDGPCDGNMIUNX-UUOKFMHZSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- ACEMKCOYIINOHN-UHFFFAOYSA-N 5-methyl-1h-pyrimidine-2,4-dione;pyrimidine Chemical compound C1=CN=CN=C1.CC1=CNC(=O)NC1=O ACEMKCOYIINOHN-UHFFFAOYSA-N 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- YHKANGMVQWRMAP-DCAQKATOSA-N Ala-Leu-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YHKANGMVQWRMAP-DCAQKATOSA-N 0.000 description 1
- MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 description 1
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- 101100162658 Alternaria alternata AMT6 gene Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- WVRUNFYJIHNFKD-WDSKDSINSA-N Arg-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N WVRUNFYJIHNFKD-WDSKDSINSA-N 0.000 description 1
- URAUIUGLHBRPMF-NAKRPEOUSA-N Arg-Ser-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O URAUIUGLHBRPMF-NAKRPEOUSA-N 0.000 description 1
- 241001123248 Arma Species 0.000 description 1
- SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 description 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
- ZBYLEBZCVKLPCY-FXQIFTODSA-N Asp-Ser-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZBYLEBZCVKLPCY-FXQIFTODSA-N 0.000 description 1
- NAAAPCLFJPURAM-HJGDQZAQSA-N Asp-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O NAAAPCLFJPURAM-HJGDQZAQSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101100069049 Caenorhabditis elegans goa-1 gene Proteins 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 241001397104 Dima Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000533867 Fordia Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- GCYFUZJHAXJKKE-KKUMJFAQSA-N Glu-Arg-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GCYFUZJHAXJKKE-KKUMJFAQSA-N 0.000 description 1
- TUTIHHSZKFBMHM-WHFBIAKZSA-N Glu-Asn Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O TUTIHHSZKFBMHM-WHFBIAKZSA-N 0.000 description 1
- GTFYQOVVVJASOA-ACZMJKKPSA-N Glu-Ser-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N GTFYQOVVVJASOA-ACZMJKKPSA-N 0.000 description 1
- HQTDNEZTGZUWSY-XVKPBYJWSA-N Glu-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O HQTDNEZTGZUWSY-XVKPBYJWSA-N 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- QCTLGOYODITHPQ-WHFBIAKZSA-N Gly-Cys-Ser Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O QCTLGOYODITHPQ-WHFBIAKZSA-N 0.000 description 1
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 1
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- YTKOTXRIWQHSAZ-GUBZILKMSA-N His-Glu-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N YTKOTXRIWQHSAZ-GUBZILKMSA-N 0.000 description 1
- XDIVYNSPYBLSME-DCAQKATOSA-N His-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N XDIVYNSPYBLSME-DCAQKATOSA-N 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UQXADIGYEYBJEI-DJFWLOJKSA-N Ile-His-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N UQXADIGYEYBJEI-DJFWLOJKSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- 241001103596 Lelia Species 0.000 description 1
- JUWJEAPUNARGCF-DCAQKATOSA-N Leu-Arg-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JUWJEAPUNARGCF-DCAQKATOSA-N 0.000 description 1
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
- LOLUPZNNADDTAA-AVGNSLFASA-N Leu-Gln-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LOLUPZNNADDTAA-AVGNSLFASA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- ORWTWZXGDBYVCP-BJDJZHNGSA-N Leu-Ile-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(C)C ORWTWZXGDBYVCP-BJDJZHNGSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- NFLFJGGKOHYZJF-BJDJZHNGSA-N Lys-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN NFLFJGGKOHYZJF-BJDJZHNGSA-N 0.000 description 1
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000283956 Manis Species 0.000 description 1
- LMKSBGIUPVRHEH-FXQIFTODSA-N Met-Ala-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(N)=O LMKSBGIUPVRHEH-FXQIFTODSA-N 0.000 description 1
- ULNXMMYXQKGNPG-LPEHRKFASA-N Met-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N ULNXMMYXQKGNPG-LPEHRKFASA-N 0.000 description 1
- BMHIFARYXOJDLD-WPRPVWTQSA-N Met-Gly-Val Chemical compound [H]N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O BMHIFARYXOJDLD-WPRPVWTQSA-N 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100004031 Mus musculus Aven gene Proteins 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 101100534581 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tca-8 gene Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000002390 Pandanus odoratissimus Species 0.000 description 1
- 235000005311 Pandanus odoratissimus Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- CSDMCMITJLKBAH-SOUVJXGZSA-N Phe-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O CSDMCMITJLKBAH-SOUVJXGZSA-N 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- ONPFOYPPPOHMNH-UVBJJODRSA-N Pro-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@@H]3CCCN3 ONPFOYPPPOHMNH-UVBJJODRSA-N 0.000 description 1
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 1
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- APIDTRXFGYOLLH-VQVTYTSYSA-N Thr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)[C@@H](C)O APIDTRXFGYOLLH-VQVTYTSYSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- FBVGQXJIXFZKSQ-GMVOTWDCSA-N Tyr-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N FBVGQXJIXFZKSQ-GMVOTWDCSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- QGFPYRPIUXBYGR-YDHLFZDLSA-N Val-Asn-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N QGFPYRPIUXBYGR-YDHLFZDLSA-N 0.000 description 1
- FMPUTJLSQLIZJJ-DCAQKATOSA-N Val-Leu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FMPUTJLSQLIZJJ-DCAQKATOSA-N 0.000 description 1
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 1
- NGXQOQNXSGOYOI-BQFCYCMXSA-N Val-Trp-Gln Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 NGXQOQNXSGOYOI-BQFCYCMXSA-N 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- -1 amino EPO Chemical compound 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 108010036027 erythrogenin Proteins 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 102000056245 human TLE5 Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- FESBVLZDDCQLFY-UHFFFAOYSA-N sete Chemical compound [Te]=[Se] FESBVLZDDCQLFY-UHFFFAOYSA-N 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56102483A | 1983-12-13 | 1983-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA92130214B1 true SA92130214B1 (ar) | 2004-02-10 |
Family
ID=24240332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA92130214A SA92130214B1 (ar) | 1983-12-13 | 1992-10-31 | انتاج اريثروبوينين Erythropoietin |
Country Status (4)
Families Citing this family (346)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US5683688A (en) * | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
| US5322837A (en) * | 1985-01-11 | 1994-06-21 | Genetics Institute, Inc. | Homogeneous erythropoietin compositions and methods of using same |
| DE3688418T2 (de) * | 1985-02-13 | 1993-08-26 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US5089396A (en) * | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| US4935350A (en) * | 1985-11-18 | 1990-06-19 | Amgen | Materials and methods for controlling plasmid copy number and stability |
| DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| US5643791A (en) * | 1986-08-07 | 1997-07-01 | University Of British Columbia | Characterization and structure of an endodglucanase gene of Cellulomonas fimi |
| US4954437A (en) * | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
| US5013718A (en) * | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| US6238889B1 (en) * | 1986-12-16 | 2001-05-29 | Dsm N.V. | Molecular cloning and expression of the Pro8 isoform of human IL-3 |
| US5214132A (en) * | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
| US5194592A (en) * | 1986-12-23 | 1993-03-16 | Kyowa Hakko Kogyo Co. Ltd. | Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor |
| US4952395A (en) * | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
| US4965251A (en) * | 1987-04-03 | 1990-10-23 | The Board Of Regents Of The University Of Washington | Pulse treatment of hemoglobinopathies with erythropoietin |
| US5312810A (en) * | 1987-05-20 | 1994-05-17 | The University Of Melbourne | Method and compositions for making ACSF and ACSF antagonists |
| EP0362272B1 (en) * | 1987-05-20 | 1993-11-18 | Genentech, Inc. | Method and compositions for making acsf and acsf antagonists |
| US5328988A (en) * | 1987-10-26 | 1994-07-12 | Immunex Corporation | Interleukin-7 |
| US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| US6384194B1 (en) * | 1987-12-16 | 2002-05-07 | Dsm N.V. | Expression and purification of human interleukin-3 and muteins thereof |
| GB8810400D0 (en) * | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US7811751B2 (en) * | 1988-05-03 | 2010-10-12 | Oxford Gene Technology Limited | Analysing polynucleotide sequences |
| AP129A (en) * | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| WO1990012877A1 (en) * | 1989-04-19 | 1990-11-01 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
| IL94183A (en) | 1989-05-05 | 2003-09-17 | Baylor College Medicine | cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE |
| US5849881A (en) * | 1989-05-05 | 1998-12-15 | Baylor College Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms |
| US5571697A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine Texas Medical Center | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus |
| US6100054A (en) * | 1989-05-05 | 2000-08-08 | Baylor College Of Medicine | Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms |
| US5571691A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| US5766939A (en) * | 1989-05-05 | 1998-06-16 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| DE3923963A1 (de) * | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
| DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| US6932968B1 (en) | 1989-07-26 | 2005-08-23 | Dade Behring Marburg Gmbh | Erythropoietin (EPO) peptides and antibodies directed against these |
| US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
| KR100263845B1 (ko) * | 1989-10-13 | 2000-08-16 | 스튜어트 엘.왓트 | 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물 |
| US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| US7144731B2 (en) * | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
| US20040181044A1 (en) * | 1989-10-16 | 2004-09-16 | Zsebo Krisztina M. | Method of stimulating growth of epithelial cells by administering stem cell factor |
| US6852313B1 (en) | 1989-10-16 | 2005-02-08 | Amgen Inc. | Method of stimulating growth of melanocyte cells by administering stem cell factor |
| ZA907921B (en) | 1989-10-16 | 1991-08-28 | Amgen Inc | Stem cell factor |
| US20030186913A1 (en) * | 1990-03-21 | 2003-10-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
| JP3249147B2 (ja) * | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
| US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| DE69127829T2 (de) * | 1990-11-26 | 1998-03-19 | Chiron Corp., Emeryville, Calif. | Expression von pace in wirtszellen und verfahren zu dessen verwendung |
| US5461032A (en) * | 1991-03-01 | 1995-10-24 | Fmc Corporation | Insecticidally effective peptides |
| US5272070A (en) * | 1991-03-08 | 1993-12-21 | Board Of Regents, The University Of Texas System | Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby |
| US5863783A (en) * | 1991-03-27 | 1999-01-26 | Gist-Brocades, N.V. | Cloning and expression of DNA molecules encoding arabinan-degrading enzymes of fungal origin |
| ATE238417T1 (de) | 1991-11-04 | 2003-05-15 | Inst Genetics Llc | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| US5968502A (en) * | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US6063630A (en) * | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
| IL104419A0 (en) * | 1992-01-24 | 1993-05-13 | Fmc Corp | Insecticidally effective peptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| DE69327247T2 (de) * | 1992-09-09 | 2000-05-18 | Nippon Kayaku K.K., Tokio/Tokyo | Physiologisch aktive substanz nk175203, verfahren zu deren herstellung und pharmazeutische verwendung |
| US5989887A (en) * | 1992-11-25 | 1999-11-23 | Dsm N.V. | Cloning and expression of DNA molecules incoding arabinan-degrading enzymes of fungal origin |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| ES2229216T3 (es) | 1993-03-08 | 2005-04-16 | MERCK & CO., INC. | Composiciones de receptores nicotinicos neurales humanos de acetilcolina y procedimientos que emplean las mismas. |
| AU6709794A (en) * | 1993-04-21 | 1994-11-08 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
| AU679228B2 (en) * | 1993-04-27 | 1997-06-26 | Symbiotech, Inc. | Method of detecting compounds utilizing chemically modified lambdoid bacteriophage |
| US5650267A (en) * | 1993-04-27 | 1997-07-22 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
| US5457178A (en) * | 1993-07-07 | 1995-10-10 | Fmc Corporation | Insecticidally effective spider toxin |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| US5459031A (en) * | 1993-11-05 | 1995-10-17 | Amgen Inc. | Methods for controlling sialic acid derivatives in recombinant glycoproteins |
| GB2287941B (en) * | 1993-11-08 | 1998-01-28 | Salk Inst Biotech Ind | Human alpha2 neuronal nicotinic acetylcholine receptor compositions and methods employing same |
| US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
| US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| PT733109E (pt) | 1993-12-07 | 2006-07-31 | Genetics Inst Llc | Proteinas morfogeneticas dos 0ss0s pmo-12 e pmo-13 e as suas composicoes para inducao de tendao |
| JPH07163368A (ja) * | 1993-12-15 | 1995-06-27 | Hayashibara Biochem Lab Inc | 組換えｄｎａとその組換えｄｎａを含む形質転換体 |
| US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
| US6242417B1 (en) | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
| US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5888774A (en) * | 1994-12-19 | 1999-03-30 | Cangene Corporation | Recombinant DNA molecules and expression vectors for erythropoietin |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5885971A (en) | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
| US6531455B1 (en) * | 1995-03-24 | 2003-03-11 | The Regents Of The University Of California | Delivery of polynucleotides by secretory gland expression |
| US5756459A (en) * | 1995-06-07 | 1998-05-26 | Fmc Corporation | Insecticidally effective peptides isolatable from phidippus spider venom |
| US6485967B1 (en) | 1995-06-07 | 2002-11-26 | Merck & Co., Inc. | Human neuronal nicotinic acetylcholine receptor α6 and β3 nucleic acid |
| DE69638058D1 (de) | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
| WO1997035977A1 (en) | 1996-03-27 | 1997-10-02 | Brigham And Women's Hospital | Polycation-sensing receptor in aquatic species and methods of use thereof |
| ES2301178T3 (es) | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
| US5817343A (en) * | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
| US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
| US6004808A (en) * | 1996-06-21 | 1999-12-21 | Aurora Biosciences Corporation | Promiscuous G-protein compositions and their use |
| US6967092B1 (en) | 1996-10-25 | 2005-11-22 | Mc Kearn John P | Multi-functional chimeric hematopoietic receptor agonists |
| EP0975673A2 (en) * | 1997-04-21 | 2000-02-02 | Glycozyme, Inc. | Determination of recombinant glycosylated proteins and peptides in biological fluids |
| US5985214A (en) | 1997-05-16 | 1999-11-16 | Aurora Biosciences Corporation | Systems and methods for rapidly identifying useful chemicals in liquid samples |
| IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
| US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
| CA2312188C (en) | 1997-12-08 | 2010-06-29 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| US7569342B2 (en) | 1997-12-10 | 2009-08-04 | Sierra Molecular Corp. | Removal of molecular assay interferences |
| TW445295B (en) * | 1997-12-31 | 2001-07-11 | Shiu Li Wei | Expression vector pcDNA3.1-HC for human erythropoietin, BHK-21 host cell line transformed therewith, and production of human erythropoietin using the transformed cell |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| WO1999052562A2 (en) * | 1998-04-15 | 1999-10-21 | Lexigen Pharmaceuticals Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| AU753106B2 (en) * | 1998-04-22 | 2002-10-10 | Cornell Research Foundation Inc. | Canine erythropoietin gene and recombinant protein |
| US6696411B1 (en) * | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| US20050181482A1 (en) * | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
| DK1088084T3 (da) | 1998-06-15 | 2007-01-29 | Gtc Biotherapeutics Inc | Erythropoietin analog-humant serumalbumin fusionsprotein |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US7304150B1 (en) | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
| US6777205B1 (en) | 1998-11-06 | 2004-08-17 | Sterrenbeld Biotechnologie North America, Inc. | Host cells expressing recombinant human erythropoietin |
| BR9905867A (pt) | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula |
| BR9917606A (pt) * | 1998-11-06 | 2002-12-31 | Bio Sidus S A | Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento |
| BR9905868A (pt) | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| US7604960B2 (en) * | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US8236561B2 (en) * | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US20050170463A1 (en) * | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
| US6555343B1 (en) | 1999-05-07 | 2003-04-29 | Genentech Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| US6831060B2 (en) * | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| WO2000070060A1 (en) * | 1999-05-18 | 2000-11-23 | University Of Iowa Research Foundation | Production of complex carbohydrates |
| US7754855B1 (en) * | 1999-07-13 | 2010-07-13 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001007086A1 (en) | 1999-07-22 | 2001-02-01 | Aventis Pharmaceuticals, Inc. | Preserved pharmaceutical formulations |
| WO2001007075A2 (en) | 1999-07-22 | 2001-02-01 | Aventis Pharmaceuticals, Inc. | Multi-dose erythropoietin formulations |
| US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| HUP0202442A3 (en) * | 1999-08-09 | 2005-01-28 | Lexigen Pharmaceuticals Corp L | Multiple cytokine-antibody complexes |
| US7189392B1 (en) | 1999-10-15 | 2007-03-13 | Genetics Institute, Llc | Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins |
| CA2391226A1 (en) * | 1999-11-12 | 2001-05-17 | Baxter International, Inc. | Reduced side-effect hemoglobin compositions |
| AU2154401A (en) | 1999-11-12 | 2001-05-30 | Merck Patent Gmbh | Erythropoietin forms with improved properties |
| US6703480B1 (en) | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
| US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| US7527961B2 (en) * | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| JP2004501604A (ja) * | 2000-02-11 | 2004-01-22 | ジェネティクス インスティテュート，エルエルシー | Ｔｒａｄｅ分子およびそれに関連する使用 |
| ES2269366T3 (es) * | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
| US20020086988A1 (en) * | 2000-03-03 | 2002-07-04 | Conklin Darrell C. | Full length expressed polynucleotides and the polypeptides they encode |
| JP2003530847A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| EP1274728B1 (en) | 2000-04-21 | 2008-05-14 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
| CZ2003214A3 (cs) * | 2000-06-29 | 2003-08-13 | Merck Patent Gmbh | Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| DE60138404D1 (de) | 2000-09-25 | 2009-05-28 | Baylor College Medicine | Verbessertes system zur regulation der transgenexpression |
| DE60132793D1 (de) * | 2000-10-12 | 2008-03-27 | Marical Inc | Verfahren zur züchtung von nichterwachsenen anadromen fischen |
| US6475792B1 (en) | 2000-10-12 | 2002-11-05 | Marical, Llc | Methods for raising pre-adult anadromous fish |
| US6463883B1 (en) | 2000-10-12 | 2002-10-15 | Marical, Llc | Methods for raising pre-adult anadromous fish |
| US6481379B1 (en) * | 2000-10-12 | 2002-11-19 | Marical, Llc | Methods for raising pre-adult anadromous fish |
| US6463882B1 (en) * | 2000-10-12 | 2002-10-15 | Marical, Llc | Growing marine fish in freshwater |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| ES2284858T3 (es) * | 2001-02-02 | 2007-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina. |
| JP4234438B2 (ja) | 2001-03-07 | 2009-03-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ハイブリッド・イソタイプ抗体部分を含有する蛋白質の発現技術 |
| DE10112825A1 (de) * | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US6956023B1 (en) | 2001-04-19 | 2005-10-18 | University Of Florida | Materials and methods for providing nutrition to neonates |
| PL205352B1 (pl) | 2001-05-03 | 2010-04-30 | Merck Patent Gmbh | Rekombinowane przeciwciało specyficzne dla nowotworu |
| EP1399023B1 (en) | 2001-06-01 | 2008-04-30 | Wyeth | COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9; |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| CA2458261A1 (en) * | 2001-08-30 | 2003-03-06 | Stem Cell Therapeutics Inc. | Differentiation of neural stem cells and therapeutic use thereof |
| US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| US7393830B2 (en) | 2001-09-14 | 2008-07-01 | Stem Cell Therapeutics Inc. | Prolactin induced increase in neural stem cell numbers |
| AU2002325710A1 (en) * | 2001-09-18 | 2003-04-01 | Stem Cell Therapeutics Inc. | Effect of growth hormone and igf-1 on neural stem cells and therapeutic application |
| PL206975B1 (pl) | 2001-12-04 | 2010-10-29 | Merck Patent Gmbh | Immunocytokiny o modulowanej selektywności oraz ich zastosowanie |
| ATE384785T1 (de) * | 2001-12-07 | 2008-02-15 | Crucell Holland Bv | Herstellung von viren, virusisolaten, und impfstoffen |
| DE10209822A1 (de) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
| DE10209821A1 (de) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| CA2485365A1 (en) * | 2002-05-13 | 2003-11-20 | Modigenetech Ltd. | Ctp-extended erythropoietin |
| KR20060019501A (ko) * | 2002-07-01 | 2006-03-03 | 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 | 응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산 |
| EP1546198A1 (en) * | 2002-07-31 | 2005-06-29 | Stem Cell Therapeutics Inc. | Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
| US20040043009A1 (en) * | 2002-09-03 | 2004-03-04 | Donnie Rudd | Method of repairing primate mammalian tissue |
| US20040042997A1 (en) * | 2002-09-03 | 2004-03-04 | Donnie Rudd | Method of regenerating human tissue |
| US20040044300A1 (en) * | 2002-09-03 | 2004-03-04 | Donnie Rudd | Method of replenishing cells damaged by treatment for cancer |
| US20040076605A1 (en) * | 2002-09-03 | 2004-04-22 | Donnie Rudd | Method of regenerating human tissue |
| US20040077985A1 (en) * | 2002-09-03 | 2004-04-22 | Donnie Rudd | Method of replenishing cells damaged by treatment for cancer |
| US20040076620A1 (en) * | 2002-09-03 | 2004-04-22 | Donnie Rudd | Method of repairing primate mammalian tissue |
| ATE466085T1 (de) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| BR0314106A (pt) * | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Polipeptìdeos hasilados, especialmente eritropoietina hasilada |
| EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
| DE10242076A1 (de) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | HAS-Allergen-Konjugate |
| ES2314238T3 (es) * | 2002-10-08 | 2009-03-16 | Fresenius Kabi Deutschland Gmbh | Conjugados de oligosacaridos farmaceuticamente activos. |
| US7396913B2 (en) * | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
| JP4494977B2 (ja) * | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 |
| US20040132645A1 (en) * | 2003-01-03 | 2004-07-08 | Knox Susan J. | Methods for modulating effects of radiation in a subject |
| AU2004229465B2 (en) * | 2003-04-09 | 2010-04-29 | The United States Of America Department Of Veterans Affairs | Compositions and methods related to production of erythropoietin |
| MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
| US7459152B2 (en) * | 2003-04-23 | 2008-12-02 | Rush University Medical Center | Erythropoietin administration to improve graft survival |
| WO2004099396A1 (en) * | 2003-05-09 | 2004-11-18 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
| WO2004104046A1 (en) * | 2003-05-23 | 2004-12-02 | Crucell Holland B.V. | Production of recombinant igm in per.c6 cells |
| BRPI0413450A (pt) * | 2003-08-08 | 2006-10-17 | Fresenius Kabi De Gmbh | conjugados de hidroxialquil amido e g-csf |
| WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| EP1653991A2 (en) * | 2003-08-08 | 2006-05-10 | Fresenius Kabi Deutschland GmbH | Conjugates of a polymer and a protein linked by an oxime linking group |
| NZ546438A (en) | 2003-09-12 | 2010-07-30 | Wyeth Corp | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| EP1977816B1 (en) | 2003-09-26 | 2011-08-31 | 3M Innovative Properties Company | Nanoscale gold catalysts, activating agents, support media, and related methodologies useful for making such catalyst systems especially when the gold is deposited onto the support media using physical vapor deposition |
| BRPI0414887A (pt) * | 2003-09-29 | 2006-12-12 | Warren Pharmaceuticals Inc E T | métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica |
| US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| EP1673102A1 (en) * | 2003-10-17 | 2006-06-28 | Crucell Holland B.V. | Treatment and prevention of decubitus |
| EP2286791B1 (en) | 2003-12-30 | 2014-03-26 | Durect Corporation | Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents |
| AU2004309063B2 (en) | 2003-12-31 | 2010-10-28 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| US7423139B2 (en) * | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
| US7846898B2 (en) | 2004-02-13 | 2010-12-07 | Stem Cell Therapeutics Corp. | Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis |
| WO2005092928A1 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| WO2005092369A2 (en) * | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyethyl starch and erythropoietin |
| US20060018902A1 (en) * | 2004-04-09 | 2006-01-26 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| US20080038265A1 (en) * | 2004-04-09 | 2008-02-14 | Reilly Edward B | Antibodies to Erythropoietin Receptor and Uses Thereof |
| US20050227289A1 (en) * | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| US7588745B2 (en) * | 2004-04-13 | 2009-09-15 | Si Options, Llc | Silicon-containing products |
| CN101142234A (zh) * | 2004-11-11 | 2008-03-12 | 阿费麦克斯公司 | 结合红细胞生成素受体的新肽 |
| US20090249503A1 (en) * | 2004-12-06 | 2009-10-01 | Bolder Biotechnology, Inc. | Enzyme conjugates for use as detoxifying agents |
| KR20070110902A (ko) * | 2005-03-11 | 2007-11-20 | 프레제니우스 카비 도이치란트 게엠베하 | 비활성 출발 물질로부터 생물활성 당단백질의 생산 |
| EP2377884A1 (en) | 2005-05-10 | 2011-10-19 | Neoloch Aps | Neuritogenic peptides |
| US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| WO2007019646A1 (en) * | 2005-08-19 | 2007-02-22 | University Of Technology, Sydney | Liver-directed gene therapy |
| EP1762250A1 (en) * | 2005-09-12 | 2007-03-14 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
| CA2664629A1 (en) * | 2005-09-27 | 2007-04-05 | Christopher Gregg | Oligodendrocyte precursor cell proliferation regulated by prolactin |
| ES2913277T3 (es) | 2005-12-08 | 2022-06-01 | Amgen Inc | Producción mejorada de glicoproteínas utilizando manganeso |
| AU2006322028C1 (en) | 2005-12-08 | 2025-09-04 | Amgen Inc. | Improved host cells and culture methods |
| US8163880B2 (en) | 2006-02-23 | 2012-04-24 | Era Biotech S.A. | Production of biologically active proteins |
| JP2009530235A (ja) * | 2006-03-17 | 2009-08-27 | ステム セル セラピューティクス コーポレイション | 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン |
| CN101062407A (zh) | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | 促红细胞生成素在预防或治疗视网膜损伤中的用途 |
| WO2008011158A2 (en) | 2006-07-21 | 2008-01-24 | Amgen Inc. | Method of detecting and/ or measuring hepcidin in a sample |
| US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| KR101449587B1 (ko) * | 2006-09-14 | 2014-10-10 | 메드제닉스 메디칼 이스라엘 리미티드 | 장기 지속형 약물 제형 |
| WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
| US20110105734A1 (en) * | 2006-12-06 | 2011-05-05 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human erythropoietin |
| AU2008214386B2 (en) | 2007-02-02 | 2013-09-19 | Amgen Inc | Hepcidin and hepcidin antibodies |
| CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
| AU2008307482B2 (en) | 2007-10-02 | 2012-07-12 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-RNA and precursors thereof |
| ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
| EP2070951A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Method for producing a hydroxyalkyl starch derivatives with two linkers |
| EP2070950A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
| EP2574628B1 (en) | 2008-01-25 | 2015-05-20 | Amgen Inc. | Ferroportin antibodies and methods of use |
| EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| WO2009139822A1 (en) | 2008-05-01 | 2009-11-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| CN107022020A (zh) * | 2008-09-26 | 2017-08-08 | Ambrx公司 | 修饰的动物促红细胞生成素多肽和其用途 |
| US8318167B2 (en) | 2008-11-13 | 2012-11-27 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation of BMP-6 |
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| LT3421603T (lt) | 2009-05-02 | 2022-01-10 | Genzyme Corporation | Genų terapija, skirta neurodegeneraciniams sutrikimams |
| EP2490957B1 (en) | 2009-10-23 | 2016-11-23 | Amgen, Inc | Vial adapter and system |
| EA024052B1 (ru) | 2010-06-07 | 2016-08-31 | Эмджен Инк. | Устройство для доставки лекарственного средства |
| CN103260649A (zh) | 2010-06-15 | 2013-08-21 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| BR112013007385B1 (pt) | 2010-09-28 | 2022-07-26 | Amylin Pharmaceuticals, Llc | Polipeptídeo quimérico, seu uso e composição que o compreende |
| US9480624B2 (en) | 2011-03-31 | 2016-11-01 | Amgen Inc. | Vial adapter and system |
| TR201905991T4 (tr) | 2011-04-20 | 2019-05-21 | Amgen Inc | Oto enjektör aparatı. |
| HUE039289T2 (hu) | 2011-10-14 | 2018-12-28 | Amgen Inc | Fecskendõ és az összeszerelés módja |
| HK1204770A1 (en) | 2012-02-07 | 2015-12-04 | Global Bio Therapeutics, Inc. | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| EP2847219A1 (en) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anti-erythropoietin antibodies |
| CA2884887C (en) | 2012-11-21 | 2023-09-12 | Amgen Inc. | Drug delivery device including insertion member and reservoir |
| CA2893767C (en) | 2012-12-05 | 2022-11-08 | Novartis Ag | Compositions and methods for antibodies targeting epo |
| WO2014093417A1 (en) | 2012-12-12 | 2014-06-19 | University Of Virginia Patent Foundation | Compositions and methods for regulating erythropoiesis |
| US20160025749A1 (en) | 2013-03-11 | 2016-01-28 | Amgen Inc. | Protein formulations |
| TWI580452B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法 |
| WO2014138921A1 (en) | 2013-03-15 | 2014-09-18 | Apotex Inc. | Enhanced liquid formulation stability of erythropoietin alpha through purification processing |
| WO2014143770A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Body contour adaptable autoinjector device |
| WO2014144096A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| CA2904357C (en) | 2013-03-15 | 2020-09-22 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
| IL292270B2 (en) | 2013-03-22 | 2024-04-01 | Amgen Inc | Injector and method of assembly |
| MX378673B (es) | 2013-08-08 | 2025-03-10 | Global Bio Therapeutics Inc | Dispositivo de sujecion para procedimientos minimamente invasivos y usos del mismo. |
| WO2015059701A1 (en) | 2013-10-24 | 2015-04-30 | Medgenics Medical Israel Ltd. | Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof |
| AU2014340174B2 (en) | 2013-10-24 | 2019-09-12 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
| WO2015061386A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Injector and method of assembly |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| SG10201811702TA (en) | 2014-05-07 | 2019-01-30 | Amgen Inc | Autoinjector with shock reducing elements |
| CN112237662B (zh) | 2014-06-03 | 2022-10-21 | 安姆根有限公司 | 药物递送系统和使用方法 |
| CA2952609A1 (en) | 2014-06-26 | 2015-12-30 | Amgen Inc. | Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| EP3197915A4 (en) | 2014-09-22 | 2018-12-19 | Intrinsic Lifesciences LLC | Humanized anti-hepcidin antibodies and uses thereof |
| US10695506B2 (en) | 2014-10-14 | 2020-06-30 | Amgen Inc. | Drug injection device with visual and audio indicators |
| ES2898469T3 (es) | 2014-12-19 | 2022-03-07 | Amgen Inc | Dispositivo de administración de medicamentos con sensor de proximidad |
| JP2017538512A (ja) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置 |
| MX391511B (es) | 2015-02-17 | 2025-03-04 | Amgen Inc | Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas. |
| EP3261690B1 (en) | 2015-02-27 | 2021-12-15 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2017025928A2 (en) | 2015-08-12 | 2017-02-16 | Novartis Ag | Methods of treating ophthalmic disorders |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| EP3386573B1 (en) | 2015-12-09 | 2019-10-02 | Amgen Inc. | Auto-injector with signaling cap |
| US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
| US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| AU2017263558B2 (en) | 2016-05-13 | 2022-12-22 | Amgen Inc. | Vial sleeve assembly |
| US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
| US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3570917A1 (en) | 2017-01-17 | 2019-11-27 | Amgen Inc. | Injection devices and related methods of use and assembly |
| WO2018152073A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
| EP3582825A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
| EP3592403B1 (en) | 2017-03-06 | 2025-08-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
| EP3592402A1 (en) | 2017-03-07 | 2020-01-15 | Amgen Inc. | Needle insertion by overpressure |
| IL303449B2 (en) | 2017-03-09 | 2024-08-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
| WO2018172219A1 (en) | 2017-03-20 | 2018-09-27 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
| EP4241807B1 (en) | 2017-03-28 | 2025-02-19 | Amgen Inc. | Plunger rod and syringe assembly system |
| CA3061982A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
| AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
| JP7475860B2 (ja) | 2017-06-23 | 2024-04-30 | アムジエン・インコーポレーテツド | スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス |
| MA49562A (fr) | 2017-07-14 | 2020-05-20 | Amgen Inc | Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion |
| EP3655063A1 (en) | 2017-07-21 | 2020-05-27 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
| MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
| EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
| EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
| US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
| MA50614A (fr) | 2017-10-06 | 2020-08-12 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé |
| MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
| US11305026B2 (en) | 2017-11-03 | 2022-04-19 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
| US12053618B2 (en) | 2017-11-06 | 2024-08-06 | Amgen Inc. | Fill-finish assemblies and related methods |
| CA3079197A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
| CN111225696B (zh) | 2017-11-10 | 2023-07-18 | 安进公司 | 用于药物递送装置的柱塞 |
| SG11202003004RA (en) | 2017-11-16 | 2020-04-29 | Amgen Inc | Door latch mechanism for drug delivery device |
| IL273636B1 (en) | 2017-11-16 | 2025-06-01 | Amgen Inc | Autoinjector with stall and end point detection |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| US12303677B2 (en) | 2018-07-24 | 2025-05-20 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
| MX2021000748A (es) | 2018-07-24 | 2021-03-26 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
| CN112351804A (zh) | 2018-07-24 | 2021-02-09 | 安进公司 | 用于施用药物的输送装置 |
| WO2020028009A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| WO2020068623A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
| AU2019350660B2 (en) | 2018-09-28 | 2024-09-26 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| IL281712B2 (en) | 2018-10-02 | 2025-03-01 | Amgen Inc | Injection systems for drug delivery with internal force transmission |
| EP3860686A1 (en) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Drug delivery device having dose indicator |
| AU2019359801B2 (en) | 2018-10-15 | 2025-01-02 | Amgen Inc. | Platform assembly process for drug delivery device |
| AU2019361919B2 (en) | 2018-10-15 | 2024-09-26 | Amgen Inc. | Drug delivery device having damping mechanism |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
| US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| CA3137360A1 (en) | 2019-04-24 | 2020-10-29 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
| AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
| WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
| AU2022279223A1 (en) | 2021-05-21 | 2023-10-19 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
| US20250042958A1 (en) | 2021-10-08 | 2025-02-06 | Sola Biosciences Llc | Compositions and methods for the treatment of proteopathies |
| WO2023209074A1 (en) | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing |
| IL319976A (en) | 2022-11-02 | 2025-05-01 | Hoffmann La Roche | Method for producing glycoprotein compositions |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3033753A (en) * | 1959-08-31 | 1962-05-08 | Wilfrid F White | Erythropoietic factor purification |
| US3865801A (en) * | 1973-06-15 | 1975-02-11 | Atomic Energy Commission | Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol |
| US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4468464A (en) * | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
| US4264731A (en) * | 1977-05-27 | 1981-04-28 | The Regents Of The University Of California | DNA Joining method |
| US4411994A (en) * | 1978-06-08 | 1983-10-25 | The President And Fellows Of Harvard College | Protein synthesis |
| US4273875A (en) * | 1979-03-05 | 1981-06-16 | The Upjohn Company | Plasmid and process of isolating same |
| US4293652A (en) * | 1979-05-25 | 1981-10-06 | Cetus Corporation | Method for synthesizing DNA sequentially |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| JPS6045849B2 (ja) * | 1980-08-25 | 1985-10-12 | 林原 健 | ヒトエリトロポエチンの製造方法 |
| US4358535A (en) * | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
| US4503151A (en) * | 1980-12-10 | 1985-03-05 | Research Corporation | Recombinant cDNA construction method and hybrid nucleotides useful in cloning |
| US4394443A (en) * | 1980-12-18 | 1983-07-19 | Yale University | Method for cloning genes |
| JPS57149228A (en) * | 1981-03-11 | 1982-09-14 | Ajinomoto Co Inc | Novel erythropoietin and its preparation |
| CA1190838A (en) * | 1981-07-17 | 1985-07-23 | Cavit Akin | Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer |
| CA1180647A (en) * | 1981-07-17 | 1985-01-08 | Cavit Akin | Light-emitting polynucleotide hybridization diagnostic method |
| US4442205A (en) * | 1981-09-22 | 1984-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | Simian virus recombinant that directs the synthesis of hepatitis B surface antigen |
| AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US4468466A (en) * | 1982-02-16 | 1984-08-28 | The United States Of America As Represented By The Department Of Health And Human Services | Silver stains for protein in gels--a modified procedure |
| AR241654A1 (es) * | 1982-05-05 | 1992-10-30 | Genentech Inc | Procedimiento para producir activador de plasminogeno de tejido humano. |
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4558005A (en) * | 1982-09-13 | 1985-12-10 | University Patents, Inc. | Monoclonal anti-erythropoietin |
| IE56716B1 (en) * | 1983-01-19 | 1991-11-20 | Genentech Inc | Method for producing human tpa and expression vectors therefor |
| US4713339A (en) * | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) * | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4558006A (en) * | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| JPH0686480B2 (ja) * | 1983-02-21 | 1994-11-02 | 雪印乳業株式会社 | エリスロポエチン製造用モノクローナル抗体 |
| JPS60501140A (ja) * | 1983-04-22 | 1985-07-25 | アムジエン | 酵母による外因性ポリペプチドの分泌 |
| US4710473A (en) * | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
| JPH07106156B2 (ja) * | 1983-10-28 | 1995-11-15 | ジェネティックス、インスティチュ−ト | ファクタ−▲ｖｉｉｉ▼および関連生産物の製造 |
| IT1185503B (it) * | 1984-01-11 | 1987-11-12 | Univ New York | Cloni di odna di eritropietina umana |
| US4568488A (en) * | 1984-01-11 | 1986-02-04 | Lee Huang Sylvia | Reverse immunoaffinity chromatography purification method |
| GB8407498D0 (en) * | 1984-03-22 | 1984-05-02 | Biogen Nv | High copy number expression vectors |
| IL77081A (en) * | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
-
1984
- 1984-11-30 US US06/675,298 patent/US4703008A/en not_active Expired - Lifetime
- 1984-12-11 ZA ZA849625A patent/ZA849625B/xx unknown
- 1984-12-11 JP JP60500031A patent/JPS61501627A/ja active Granted
-
1992
- 1992-10-31 SA SA92130214A patent/SA92130214B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US4703008A (en) | 1987-10-27 |
| JPS61501627A (ja) | 1986-08-07 |
| JPH0217156B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-04-19 |
| ZA849625B (en) | 1985-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA92130214B1 (ar) | انتاج اريثروبوينين Erythropoietin | |
| JP3375614B2 (ja) | ヒトエリスロポエチン産生哺乳動物細胞の作製方法。 | |
| US5547933A (en) | Production of erythropoietin | |
| JP7292153B2 (ja) | 医薬製剤 | |
| EP2853536B1 (en) | Long-acting erythropoietin polypeptides and uses thereof | |
| TWI235667B (en) | Erythropoietin derivatives | |
| FI108140B (fi) | Menetelmä ja välineitä kantasolutekijän valmistamiseksi, valmistetun tuotteen käyttö, sitä sisältävä tarvikepakkaus sekä menetelmä kantasolutekijän vasta-aineen valmistamiseksi | |
| JPH06502987A (ja) | Ｏ―グリコシル化ｉｆｎ―アルファ | |
| JPH0372885A (ja) | ヒトエリスロポイエチンの変異体、それらの調製および使用 | |
| IE913426A1 (en) | Hybrid growth factors | |
| JPS63301798A (ja) | コロニー刺激因子誘導体 | |
| HK40020346A (en) | Pharmaceutical preparation | |
| SK279959B6 (sk) | Sekvencia dna, plazmid, vektor, hostiteľská bunka, | |
| AU4252400A (en) | Production of erythropoietin | |
| AU1974001A (en) | Production of erythropoietin | |
| DD251786A5 (de) | Verfahren zur Herstellung eines Polypeptids | |
| HK1174338B (en) | Pharmaceutical preparation comprising recombinant hcg | |
| HK1174338A (en) | Pharmaceutical preparation comprising recombinant hcg |